Key result
MicroRNA miR-486-3p modulates sinoatrial node pacemaker activity via HCN4 channels, offering a potential sinus tachycardia target.
Why the study?
Understanding the structural organization and molecular regulation of the SAN may support the development of novel therapeutic strategies for managing conditions such as sinus tachycardia.
Answers are grounded in this paper and cite their sources.
Insights into microRNA-based modulation of the sinoatrial node may support the development of novel therapeutic strategies for conditions like sinus tachycardia.
The sinoatrial node (SAN) functions as the primary pacemaker of the heart, initiating rhythmic electrical impulses that govern cardiac contraction. It consists of specialised pacemaker cells located between the superior vena cava and the right atrium, supported by a paranodal region that contributes to rhythm stabilisation and may serve as a secondary pacemaker during dysfunction. This review describes the structural organisation and molecular regulation of the SAN, with particular focus on the role of HCN4 ion channels and the influence of the microRNA miR-486-3p in modulating pacemaker activity. Understanding this relationship may support the development of novel therapeutic strategies for managing conditions such as sinus tachycardia, offering potential alternatives to existing pharmacological approaches.
No takes yet. Share an insight, caveat, or question.
Hanan Mohamed Nur (2025) conducted a review in Sinus tachycardia and sinoatrial node dysfunction. microRNA miR-486-3p was evaluated. The microRNA miR-486-3p modulates sinoatrial node pacemaker activity by regulating HCN4 ion channels, offering a potential novel therapeutic strategy for managing sinus tachycardia.
Synapse has enriched 10 related papers. Consider them for comparative context: